Amylin Pharmaceuticals, Inc. Release: BYDUREON™ Improved A1C, Fasting Glucose, Pulse Pressure and Weight Regardless of Baseline Body Weight in Patients With Type 2 Diabetes

PHILADELPHIA--(BUSINESS WIRE)--Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Alkermes plc (Nasdaq: ALKS) today announced results from an analysis of seven randomized clinical studies demonstrating that patients treated with BYDUREON™ (exenatide extended-release for injectable suspension), the first and only once-weekly treatment for type 2 diabetes, experienced improvements in A1C, fasting glucose, weight and pulse pressure, regardless of baseline body weight. These findings are being presented at the 72nd Scientific Sessions of the American Diabetes Association in Philadelphia.